# Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants

> **NCT00320463** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 415 (—)

## Conditions studied

- Diphtheria
- Hepatitis B
- Poliomyelitis
- Tetanus
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** DTPa-HBV-IPV/Hib vaccine

## Key facts

- **NCT ID:** NCT00320463
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 415 (—)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320463, "Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00320463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*